India Home Loan Limited approves quarterly results and board appointments

India Home Loan Limited announced its un-audited financial results for the second quarter and half year ended September 30, 2026. The Board of Directors also approved the appointment of new key personnel, including an Additional Non-Executive Independent Director and a Chief Operating Officer. The company also submitted various disclosures as per SEBI regulations, including unaudited financial results, auditor’s review report, and key financial ratios for the period.

Financial Results and Key Appointments

India Home Loan Limited has disclosed its un-audited financial results for the quarter and half year that concluded on September 30, 2026. The company’s Board of Directors convened a meeting on November 4, 2026, to consider and approve these results, alongside other significant business items. The financial statement was prepared in accordance with the Indian Accounting Standards (Ind-AS) and reviewed by H K Shah & Co., Chartered Accountants.

Board Changes and Personnel Appointments

The Board also approved the appointment of Mr. Manmohan Jindal as an Additional Non-Executive Independent Director for a term of five years, pending shareholder approval. Additionally, Mr. Mitesh M. Pujara was appointed as Chief Operating Officer and designated as a Key Managerial Personnel. Mr. Ganesh Ruvikar was appointed as Whole-time Company Secretary and Compliance Officer.

Regulatory Disclosures

In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted various disclosures. These included the financial results, an auditor’s limited review report, and specific information regarding the newly appointed directors and officers. Details of the utilization of funds raised through Non-Convertible Debentures (NCDs) were also provided, confirming no deviation in their usage for the quarter ended September 30, 2026. The company also presented various financial ratios, including Debt Equity Ratio (1.05), Net Profit Margin (0.27%), and Gross Non Performing Assets (2.74%) as of September 30, 2026.

Source: BSE

Previous Article

Entero Healthcare reports Q2 FY27 results and approves stock options

Next Article

Gujarat Kidney And Superspeciality reports no deviation in IPO fund use for Q2 2026